Daewoong Pharmaceutical Co. is strengthening its ties with Evolus Inc., a global partner for the sales of Nabota, Daewoong's self-developed botulinum toxin, as the drug is expected to be released in the U.S. market next year.
The company said the key executives of Evolus Inc., including new President David Moatazedi, visited Daewoong’s head office in Seoul and Nabota manufacturing plant in Hyangnam from Oct. 4 to 5.
The two companies discussed plans for a successful launch of Nabota in the U.S. market. The top executives of Evolus, including President David Moatazedi and chief marketing officer Michael Mazen Jafar, met with medical specialists in the U.S., developers and global marketers to share information and exchange opinions about Nabota.
Currently, Nabota is under the approval review by the U.S. Food and Drug Administration (FDA) as well as the European Medicines Agency (EMA). The toxin is forecast to be available in the market of major advanced countries, including the U.S. and Europe, in the first half of next year.
Daewoong Pharmaceutical co-CEO Jeon Seung-ho said, “Daewoong Pharmaceutical and Evolus have been gearing up in preparation for the launch of Nabota and strengthening the partnerships further so that Korean botulinum toxin Nabota can successfully enter the market of major developed countries.”